Anthera Pharma (ANTH) PT Lowered to $1.75 at Jefferies Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy
August 9, 2017 4:00 PM EDTHAYWARD, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq: ANTH) today announced that blisibimod has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A nephropathy (IgAN). Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including IgAN, systemic lupus erythematosus, and others.
We are pleased by the FDAs decision to designate blisibimod with orphan drug designation, said Craig Thompson, Chief Executive Officer of Anthera. There remains a very... More
Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results
August 9, 2017 8:30 AM EDTRESULT, pivotal Phase 3 study of Sollpura began screening patients in the U.S. and EuropeRESULT study approved by the Cystic Fibrosis Foundation Therapeutics Development NetworkBRIGHT, Phase 2 study of blisibimod in IgA Nephropathy remains on track to report topline data in Q3Executed equity purchase agreement for the sale of up to $10 million in common stock at the Companys discretionReceived extension from Nasdaq to regain listing compliance
HAYWARD, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today provided a business update and reported financial results for the... More
